**Exhibit10.1**

**LICENSE AGREEMENT**

This License Agreement (“Agreement”) is effective andentered into as of _____, 2006 (the “Effective Date”), by and between GEHealthcare AS., (“GEHC”), a Norwegian corporation with offices at  Nycoveien 1-2 Postboks 4220 Nydalen, OsloNorway and Acusphere Inc. (“ACUS”) a Delaware corporation  with offices at 500 Arsenal St., Watertown,MA 02472.  (GEHC and ACUS collectively “theParties”).

WHEREAS, GEHC owns certain patents relating to thecompositions, methods of preparing, and methods of use of ultrasound contrastagents;

WHEREAS, ACUS is developing that certain ultrasoundcontrast agent, AI-700, which is the subject of Investigational New Drug Application (“INDA”) with the U.S. Food andDrug Administration;

WHEREAS, ACUS desires to obtain a non-exclusivelicense to certain of GEHC’s patents.

 NOW, THEREFORE,in consideration of the foregoing and the covenants, acknowledgements andrepresentations contained in this Agreement, the Parties hereby agree asfollows:

# **ARTICLEI.  DEFINITIONS**

## 1.1.          Definitions.  For purposes of this Agreement, the termsdefined here shall have the meanings specified below.  These terms are intended to encompass bothsingular and plural forms.

### 1.1.1.                     “Affiliate” shall mean anentity that directly, or indirectly through one or more intermediaries,controls, or is controlled by, or is under common control with a Party.  Without limiting the generality of theforegoing, “control” shall mean the ownership, directly or indirectly, of fiftypercent (50%) or more of the issued share capital or shares of stock entitledto vote for the election of directors, in the case of a corporation, or fiftypercent (50%) or more of the equity interests in the case of any other entityor the legal power to direct or cause the direction of the general managementand policies of the entity in question.

### 1.1.2.                     “AI-700” shall mean theultrasound contrast product currently under development by ACUS and for whichACUS has filed an INDA.  The term “AI-700”includes postapproval changes made to the product  in accordance with Section 506A of thefederal Food, Drug, and Cosmetic Act and Section 314.70 (21 CFR 314.70) asrecommended in the document: GUIDANCE FOR INDUSTRY, CHANGES TO AN APPROVED NDAOR ANDA, April 2004, U.S. Department of Health 

1

----

###                                                 andHuman Services, Food and Drug Administration, Center for Drug Evaluation andresearch (CDER), April 2004, CMC, Revision 1.

### 1.1.3.                     “Field” shall meanultrasound diagnostic imaging in humans and animals.

### 1.1.4.                     “GEHC Licensed Patents”shall mean (i) all present patents and patent applications worldwide that claimthe composition of, manufacture of, or methods of use of ultrasound contrastagents, which are issued or pending as of the Effective Date, together with allfuture patents and patent applications that claim priority (directly orindirectly through other applications) to any patent or patent applicationpending as of or before the Effective Date that are owned by or licensed toGEHC or an Affiliate with a right to sublicense, including without limitation,those listed on Exhibit A hereto and (ii) all patents and patent applicationsworldwide that claim the composition of, manufacture of, or methods of use ofultrasound contrast agents which GEHC or an Affiliate acquires (by license witha right to sublicense, acquisition or otherwise (including by internalinvention)) within 12 months after the Effective Date.

### 1.1.5.                      “Territory” shall mean theentire world except Japan, the People’s Republic of China, and the Republic ofKorea.

### 1.1.6.                     “Third Party” shall meanany entity other than GEHC, ACUS, or their respective Affiliates.

# **ARTICLE II. LICENSE FROM GEHC TO ACUS**

## 2.1.            Subject to the terms and obligations of thisAgreement GEHC hereby grants ACUS, and ACUS accepts, a nonexclusive licenseunder the GEHC Licensed Patents to make, use, sell, offer to sell, and importAI-700 in the Field in the Territory.

## 2.2.          ACUS has the rightto grant distribution rights for AI-700 under the GEHC Licensed Patents and hasthe limited right to grant sublicenses to manufacturers to manufacture AI-700on behalf of ACUS, as well as to its distributors in connection with theirdistribution rights.

## 2.3.          Other than thelimited right to sublicense granted in paragraph 2.2, ACUS does not have theright to grant sublicenses.

## 2.4.          The Partiesacknowledge that nothing in this Agreement shall be construed to convey anytitle or ownership rights to the GEHC Licensed Patents.  With the exception of the rights explicitlygranted in paragraphs 2.1 through 2.2, no license, or other right, title orinterest to or under the GEHC Licensed Patents is granted by implication,estoppel or otherwise.

2

----

 

## 2.5.          To the extent required by and in conformancewith any applicable laws, ACUS shall mark AI-700 with the numbers of theapplicable GEHC Licensed Patents.

# **ARTICLEIII.  RELEASE AND COVENANT NOT TO SUE**

## 3.1.          GEHC hereby releasesACUS and its current Affiliates from all claims, allegations, damages,obligations, liabilities or expenses of any kind or nature that it may haveagainst any of them, subject to the limitation of paragraph 3.3.  This releases all claims and obligationsresulting from anything which has happened up to now, including claims of whichGEHC is not aware, and specifically including without limitation all claims orinfringement of GEHC Licensed Patents on account of the manufacture, use, sale,offer for sale, and importation of AI-700 up to and including the EffectiveDate.

## 3.2.          ACUS hereby releasesGEHC and its current Affiliates from all claims, allegations, damages, obligations,liabilities or expenses of any kind or nature that it may have against any ofthem.  This releases all claims andobligations resulting from anything which has happened up to now, includingclaims of which ACUS is not aware, and specifically including withoutlimitation all claims or infringement of any ACUS patent on account of themanufacture, use, sale, offer for sale, and importation of ultrasound contrastagents up to and including the Effective Date.

## 3.3.          None of the releasesabove shall be construed in any way as being a release of any indebtedness toany GEHC Affiliate under any loan agreement, security interest, agreement ofindebtedness, security interest, or other agreement for the loan of money,extension of credit, provision of services, or sale or lease of goods.

## 3.4.          To the extent thatit may apply to Agreement, the parties waive any and all rights underCalifornia Civil Code § 1542 (as well as any similar statute or law in anyother jurisdiction), which section has been duly explained to each of theparties by their respective counsel, and which reads as follows: “A generalrelease does not extend to claims which the creditor does not know or suspectto exist in his favor at the time of executing the release, which if known byhim must have materially affected his settlement with the debtor.”

## 3.5.          ACUS, for itself andits current and future Affiliates, covenants not to sue GEHC or its Affiliatesfor infringement of any patent on account of GEHC or its Affiliates’manufacture, use, sale, or offer to sell of Optison or Sonazoid in theTerritory for use in the Field.  Thiscovenant shall extend to GEHC’s distributors and customers on account of theirpurchase, sale, or use of Sonazoid or Optison in the Territory for use in theField.

3.6           GEHC, for itself and its current andfuture Affiliates, covenants not to sue ACUS or its Affiliates for infringementof any patent on account of ACUS or its Affiliates’ manufacture, use, sale, oroffer to sell AI-700 in the Territory for use in the Field.  This covenant shall extend to ACUS’sdistributors and customers on account of their purchase, sale, or use of AI-700in the Territory for use in the Field.

3

----

## 3.7           Itis the intention of the parties to settle current and potential intellectualproperty disputes pertaining to the GEHC Licensed Patents and patents that ACUShas in the Field. In that connection, the parties shall:

## 3.7.1.                     withdrawall current oppositions brought against the other’s patents for the Field incountries foreign to the United States;

### 3.7.2.                     refrainfrom filing any future opposition or other challenge against the claims of eachother’s patents relating to Optison, Sonazoid or AI-700  in countries foreign to the United States;and

### 3.7.3.                     refrainfrom filing any requests for interference, reexamination, protest or otherchallenge against the claims of each other’s patents relating Optison, Sonazoidor AI-700  in the United States.

# **ARTICLE IV. FEES, PAYMENTS, WARRANTIES, INDEMNIFICATION**

## 4.1.          In consideration ofthe licenses and release granted in Section 3, ACUS shall make the followingpayments to GEHC:

### 4.1.1.                     An upfrontlicense fee of $10,000,000 paid in two installments of:

#### a)     $5,000,000 within five business days afterexecution of this Agreement.

#### b)    $5,000,000 on the first anniversary of theEffective Date,

#### said fees to be non-contingent andnon-returnable.

### 4.1.2.                     A license feeof $10,000,000 paid in two installments of:

#### a)     $5,000,000 within five business days afterthe earlier of (i) receipt of regulatory approval by the U.S. Food and DrugAdministration to market AI-700 or (ii) the approval of a MarketingAuthorization Application in Europe related to AI-700.

#### b)    $5,000,000 upon the one year anniversary ofthe payment set forth in paragraph 4.1.2(a),

#### said fees tobe non-returnable.

## 4.2.          All payments by ACUSto GEHC shall be by wire transfer of same day federal funds to the followingaccount (or any alternative account which GEHC designates to ACUS prior to thedue date of any of the payments set forth in paragraph 4.1).

Bank Name: BNP ParibasLondon Branch

Name on Account: Amersham Health AS

4

----

SWIFT-BIC: BNPAGB22

IBAN: GS89 BNPA23463574375010

Account No.  09678 074375 00191

## 4.3.          Any payments made under Section 4 ofthis Agreement are inclusive of any tax imposed upon such payments.  In addition, in the event any of the paymentsmade by ACUS pursuant to Section 4 are subject to withholding taxes underthe laws of any jurisdiction, ACUS shall consult GEHC in advance and take allreasonable actions, on a timely basis, to reduce the level of withholding tothe minimum permitted under the laws of the jurisdiction having regard to theterms of any relevant double tax treaty. Should a withholding tax still be due,such amounts payable to GEHC shall be reduced by the amount of taxes deductedand withheld, and ACUS shall pay the amounts of such taxes to the propergovernmental authority in a timely manner and promptly transmit to GEHC anofficial tax certificate or other evidence of such tax obligations togetherwith proof of payment from the relevant governmental authority of all amountsdeducted and withheld sufficient to enable GEHC to claim such payment oftaxes.  ACUS will provide GEHC withreasonable assistance to enable GEHC to recover such taxes as permitted by law.

## 4.4.          All payments under any provision ofthis Agreement shall bear interest from the date due until paid at a rate equalto the lesser of (i) five percentage points above the prime rate of Citibank, N.A. (or its successor) in NewYork, New York, as announced on the date such payment was due, or (ii)the highest amount allowable by law, compounded monthly.  In addition, ACUS shall reimburse GEHC forall reasonable costs and expenses, including without limitation reasonableattorneys’ fees and legal expenses, incurred in the collection of late ormissed payments.

## 4.5.          Each Party shall bear its own costsand expenses, including, without limitation, its attorneys fees, relating toany action to be taken or having been taken in respect to this Agreement.

## 4.6.          Each Party makes the followingwarranties and representations to the other Party:

### 4.6.1.                     each Party is a corporation dulyorganized and validly existing and in good standing under the laws of the stateor country in which it is organized and has all requisite power and authorityto enter into and perform this Agreement and the transactions contemplatedhereby and to require its Affiliates to abide by its terms and conditions;

### 4.6.2.                     all requisite corporate action onthe part of each Party has been completed for the authorization of theexecution and delivery of this Agreement and the performance of the transactioncontemplated hereunder;

5

----

### 4.6.3.                     this Agreement is, and such othertransactions will be, valid and binding obligations of each Party enforceablein accordance with their respective terms; and

### 4.6.4.                     the execution, delivery andperformance of this Agreement and the consummation of transactions contemplatedhereby do not and will not violate the provisions of any Party’s certificate ofincorporation or bylaws or similar type documents or the provisions of anynote, indenture, lease, license permit or other instrument or obligation orviolate any law, order, rule or regulation applicable to it.

## 4.7.          Nothing in this Agreement shall be construed as a warrantyor representation by GEHC as to the validity of any GEHC Licensed Patent orthat AI-700 is free from infringement of domestic or foreign patents or otherproprietary interests of other parties. GEHC IS LICENSING THE GEHC LICENSEDPATENTS TO ACUS ON AN “AS IS” BASIS. GEHC MAKES NO WARRANTIES EITHER EXPRESS OR IMPLIED OF ANY KIND, ANDHEREBY EXPRESSLY DISCLAIMS ANY WARRANTIES, REPRESENTATIONS OR GUARANTEES OF ANYKIND AS TO THE GEHC LICENSED PATENTS, THE SUBJECT OF ANY LICENSE HEREUNDERAND/OR ANY PRODUCTS, INCLUDING BUT NOT LIMITED TO, ANY WARRANTIES OFMERCHANTABILITY, FITNESS, ADEQUACY OR SUITABILITY FOR A PARTICULAR PURPOSE, USEOR RESULT, AND ANY WARRANTIES OF FREEDOM OF INFRINGEMENT OF ANY PATENTS,COPYRIGHTS, TRADE SECRETS OR OTHER PROPRIETARY RIGHTS.  NEITHER GEHC, NOR ANY EMPLOYEE OR AGENT OFGEHC, SHALL HAVE ANY LIABILITY TO ACUS, ITS AFFILIATES, OR SUBLICENSEES, OR ANYOTHER PERSON ARISING OUT OF THE USE OF GEHC LICENSED PATENTS OR PRODUCTSINCLUDING BUT NOT LIMITED TO THE LACK OF MERCHANTABILITY, INADEQUACY ORUNSUITABILITY OF THE GEHC LICENSED PATENTS OR PRODUCTS FOR ANY PARTICULARPURPOSE OR TO PRODUCE ANY PARTICULAR RESULT, OR FOR ANY LATENT DEFECTS THEREIN.

## 4.8.          ACUS shall indemnifyand hold GEHC and its Affiliates harmless against any and all third-partyactions, suits, claims, demands, prosecutions, liabilities, costs, expenses,damages, deficiencies, loss or obligations (including reasonable attorneys’fees) based on or arising out of this Agreement, including, without limitation,(i) the development, manufacture, packaging, use, or sale of AI-700 (ii) thepractice of the GEHC Licensed Patents by ACUS, its Affiliates, its Sublicenseesor its (or their) customers and (iii) any representation made or warranty givenby ACUS, its Affiliates with respect to GEHC Licensed Patents or AI-700.

## 4.9.          ACUS shall maintain, during the term of thisAgreement, commercial general liability insurance, including product liabilityinsurance, with reputable and financially secure insurance carriers, oncommercially reasonable and prudent terms and limits.

## 4.10.        ACUS and its current and future Affiliatesshall not directly or indirectly challenge or induce any Third Party tochallenge the validity or enforceability of the GEHC Licensed Patents, or anypatent claim(s) therein, or initiate or participate in any re-examination orother proceeding related to the validity, enforceability or patentability ofany 

6

----

## claimof the GEHC Licensed Patents before any tribunal or patent office.  This section shall not prohibit ACUS and itsAffiliates from responding to a subpoena, process, or discovery requests in anylitigation or administrative proceeding provided that ACUS gives prompt noticeto GEHC of the receipt of said subpoena, process or discovery requests.

# **ARTICLE V. DURATION**

## 5.1.          The term of the licensesgranted by GEHC shall be until the last to expire of the GEHC Licensed Patents.

# **ARTICLEVI.  CONFIDENTIALITY**

## 6.1.          NoParty shall disclose the contents of this Agreement to any other person orentity and each Party shall retain in confidence the terms and conditions ofthis Agreement, except as necessary to comply with law or the valid order of acourt or agency of competent jurisdiction of a state or federal authority; orto the extent necessary in any action, suit or proceeding to enforce this Agreement;or to their respective Affiliates, banks, auditors, accountants, lawyers, andany other representative of a Party who has a good faith need to know, providedthat any such person or entity to whom disclosure is made must be advised ofthe confidentiality of the information disclosed and agree to keep suchinformation confidential.

## 6.2.          No public statementsof any kind pertaining to this Agreement may be made except as required by law,such as that enforced by the Securities Exchange Commission of the UnitedStates of America, unless the parties otherwise mutually agree in writing.  Attached hereto as Exhibit __is a form ofpress release that the parties agree shall be issued by ACUS  promptly after the execution of thisAgreement.

# **ARTICLE VII. MISCELLANEOUS**

## 7.1.          Notice:  All notices or communications requiredpursuant to this Agreement shall be in writing and shall be deemed to have beenduly given upon the date of receipt if delivered by hand, internationalovernight courier, confirmed facsimile transmission, or registered or certifiedmail (return receipt requested, postage prepaid) to the following addresses orfacsimile numbers:

| For GEHC: |                         |   | GE Healthcare AS. |   |
|-----------|------------------------------|--------|-------------------|--------|
|      | c/o GE  Healthcare           |   |
|      |                         |   |
|      | Nycoveien 1-2  Postboks 4220 |   |
|      | Nycalen, Oslo  Norway        |   |
|      | Attn: General  Counsel       |   |
|      | Fax:  47-2222-9865           |   |
|      |                         |   |
| For ACUS: |                         |   | Sherri Oberg      |   |   |   |
|      | Acusphere Inc.               |   |              |   |
|      | 500 Arsenal Street           |   |              |   |
|           |                              |        |                   |        |  |  |  |  |  |  |  |  |

 

7

----

 
|        | Watertown, MA 02472 |   |   |   |
|--------|---------------------|--------|--------|--------|
|   | FAX 617-926-3605    |   |   |   |
|        |                     |        |        |        |  |  |

##  

## 7.2.          Choice of Law andForum:  The Parties agree that thisAgreement shall be governed by the laws of the State of New York withoutreference to its conflict of laws principles. Any legal action or proceeding arising out of or in connection with thisAgreement or other aspect of the Parties’ relationship shall be brought only inthe state or federal courts located in New York County, New York, and eachParty hereby consents to the jurisdiction of such courts for any such matter.

## 7.3.          Entire Agreement:  This Agreement sets forth all the licenses, covenants,promises, agreements, warranties, representations, conditions, andunderstandings between the Parties hereto and supersede all prior agreementsand understandings between the Parties relating to the subject matter hereof.  This Agreement, including, withoutlimitation, the Exhibits attached hereto, is intended to define the full extentof the legally enforceable undertakings of the Parties hereto.

## 7.4.          Severability:  In the event that any provision of thisAgreement shall, for any reason, be held to be invalid or unenforceable in anyrespect, such invalidity or unenforceability shall not affect any otherprovision hereof, and the Parties shall negotiate in good faith to modify theAgreement to preserve their original intent.

## 7.5.          Amendment and Waiver:  This Agreement may be amended, supplemented,or otherwise modified only by means of a written instrument signed by allParties.  Any waiver of any rights orfailure to act in a specific instance shall relate only to such instance andshall not be construed as an agreement to waive any rights or fail to act inany other instance, whether or not similar.

## 7.6.          Breach and Cure: Either party shall have the right to cure its material breach.  The cure shall be effected within areasonable period of time but in no event later than twenty (20) days afternotice of any breach given by the non-breaching party, or five (5) businessdays in the event of a payment obligation.

## 7.7.          Headings:  The sections and paragraphs headingscontained herein are for the purposes of convenience only and are not intendedto define or limit the contents of said sections or paragraphs.

## 7.8.          Counterparts:  This Agreement may be signed in counterpart,each of which shall be deemed to be an original.  Signatures shall be provided by facsimiletransmission, with original signatures following by mail.

## 7.9.          Assignment:  ACUS may not assign this Agreement nor thelicenses granted herein to any Third Party unless said assignment is to asuccessor by merger, acquisition, or corporate reorganization, and/or inconnection with the sale or other disposition by license, joint venture orotherwise of the entire business unit or product(s) to which this Agreementpertains and assignee must agree to the terms of this Agreement on behalf ofitself and its Affiliates, including but not limited to the provisions of  paragraphs 3.5 and 4.10.  For 

8

----

## avoidance of doubt, the release of paragraph 3.1 shall not extend tothe assignee’s business or assets other than those acquired from ACUS.

## 7.10.        Subsequent Acquisitions:  If, after the Effective Date, ACUS or anAffiliate either acquires an entity or acquires substantially all of the assetsfrom an entity, and said entity is, immediately prior to the date ofacquisition, licensed by the other party (“Licensor”) under one or more GEHCLicensed Patents through an existing agreement pursuant to which royalties orother payments are made by said entity to Licensor, then the license and otherrights granted herein to the Acquiring Party with respect to said GEHC LicensedPatents shall apply to products manufactured by said entity or through the useof said assets, provided that such royalties or other payments shall continueto be made by the Acquiring Party or said entity to the Licensor with respectto such products notwithstanding that the Acquiring Party may have beenlicensed for the same products before the acquisition.  For avoidance of doubt, the release ofparagraph 3.1 shall not extend to any entity whose assets are acquired orsubstantially acquired by ACUS.

IN WITNESS WHEREOF, the undersigned Parties have dulyexecuted and delivered this Agreement as of the date first written above.

| **GE Healthcare AS.** |       | **Acusphere, Inc.** |
|-----------------------|------------|---------------------|
| ** **            | ** ** |
| By:                   |       |                | By: |   |
|                  |       |                |
| Name:                 |       |                | Name: |   |
|                  |       |                |   |
| Title:                |       |                | Title: |   |
|                  |       |                |   |
| Date:                 |       |                | Date: |   |
|                  |       |                |
|                       |            |                     |  |  |  |  |

 

 

9

----

**SCHEDULE A**
| **Title**                                       | ** ** | ** ** | ** ** | **Country** | ** ** | **Patent No.** | ** ** | **Application No.** |
|-------------------------------------------------|------------|------------|------------|-------------|------------|----------------|------------|---------------------|
| Diagnostic and contrast  agent                  |       | US         |       | 5618514     |       |           |
|                                            |       |       |       | 6544496     |       |           |
|                                            |       |       |       | 5670135     |       |           |
|                                            |       |       |       |        |       |           |
| IMPROVEMENTS IN OR  RELATING TO CONTRAST AGENTS |       | CH         |       | 0576519     |       |           |
|                                            |       | DE         |       | 69231794.5  |       |           |
|                                            |       | ES         |       | 2156109     |       |           |
|                                            |       | FR         |       | 0576519     |       |           |
|                                            |       | GB         |       | 0576519     |       |           |
|                                            |       | HK         |       | 1004980     |       |           |
|                                            |       | IT         |       | 0576519     |       |           |
|                                            |       | NO         |       |        |       | 19933431       |
|                                            |       | US         |       | 5536490     |       |           |
|                                            |       | US         |       |        |       | 08/470044      |
|                                            |       | US         |       | 6106806     |       |           |
|                                            |       | US         |       | 5567413     |       |           |
|                                            |       | US         |       |        |       | 10/449832      |
|                                            |       |       |       |        |       |           |
| IMPROVEMENTS IN OR  RELATING TO CONTRAST AGENTS |       | DE         |       | 0831926     |       |           |
|                                            |       | EP         |       | 0831926     |       |           |
|                                            |       | ES         |       | 0831926     |       |           |
|                                            |       | FR         |       | 0831926     |       |           |
|                                            |       | GB         |       | 0831926     |       |           |
|                                            |       | IT         |       | 0831926     |       |           |
|                                            |       | US         |       | 6217850     |       |           |
|                                            |       |       |       |        |       |           |
| IMPROVEMENTS IN OR  RELATING TO CONTRAST AGENTS |       | AT         |       | E238072     |       |           |
|                                            |       | AU         |       | 726503      |       |           |
|                                            |       | BR         |       |        |       | PI1100844.0    |
|                                            |       | CZ         |       | 293986      |       |           |
|                                            |       | DE         |       | 0881915     |       |           |
|                                            |       | EP         |       | 0881915     |       |           |
|                                            |       | ES         |       | 0881915     |       |           |
|                                            |       | FR         |       | 0881915     |       |           |
|                                            |       | GB         |       | 0881915     |       |           |
|                                            |       | HK         |       | HK1014872   |       |           |
|                                            |       | IE         |       | 0881915     |       |           |
|                                            |       | IL         |       | 125748      |       |           |
|                                            |       | IT         |       | 0881915     |       |           |
|                                            |       | NL         |       | 0881915     |       |           |

 

10

----

 
|                                            |   | NO     |   | 318875      |   |   |
|-------------------------------------------------|--------|--------|--------|-------------|--------|--------|
|                                            |   | PH     |   | 1997-55604  |   |   |
|                                            |   | PT     |   | 0881915     |   |   |
|                                            |   | RU     |   | 001135      |   |   |
|                                            |   | US     |   | 6221337     |   |   |
|                                            |   | ZA     |   | 97/1408     |   |   |
|                                            |   |   |   |        |   |   |
| THERMALLY STABILIZED  CONTRAST AGENT            |   | DE     |   | 0885016     |   |   |
|                                            |   | EP     |   | 0885016     |   |   |
|                                            |   | ES     |   | 0885016     |   |   |
|                                            |   | FR     |   | 0885016     |   |   |
|                                            |   | GB     |   | 0885016     |   |   |
|                                            |   | IT     |   | 0885016     |   |   |
|                                            |   | US     |   | 6165442     |   |   |
|                                            |   | US     |   | 6562320     |   |   |
|                                            |   |   |   |        |   |   |
| PROCESS FOR PREPARATION  OF VESICLES            |   | DE     |   | 69806020.2  |   |   |
|                                            |   | DE     |   | 1007102     |   |   |
|                                            |   | EP     |   | 1005391     |   |   |
|                                            |   | EP     |   | 1007102     |   |   |
|                                            |   | GB     |   | 1007102     |   |   |
|                                            |   | US     |   | 6444193     |   |   |
|                                            |   | US     |   | 6509004     |   |   |
|                                            |   |   |   |        |   |   |
| IMPROVEMENTS IN OR  RELATING TO CONTRAST AGENTS |   | AT     |   | 0576521     |   |   |
|                                            |   | AU     |   | 701817      |   |   |
|                                            |   | BE     |   | 0576521     |   |   |
|                                            |   | CA     |   | 2107107     |   |   |
|                                            |   | CH     |   | 0576521     |   |   |
|                                            |   | DE     |   | P69222037.2 |   |   |
|                                            |   | DK     |   | 0576521     |   |   |
|                                            |   | EP     |   | 0576521     |   |   |
|                                            |   | ES     |   | 2106857     |   |   |
|                                            |   | FI     |   |        |   | 934227 |
|                                            |   | FR     |   | 0576521     |   |   |
|                                            |   | GB     |   | 0576521     |   |   |
|                                            |   | GR     |   | 20040401146 |   |   |
|                                            |   | HK     |   | 1002624     |   |   |
|                                            |   | IE     |   | 82203       |   |   |
|                                            |   | IT     |   | 0576521     |   |   |
|                                            |   | LU     |   | 0576521     |   |   |
|                                            |   | MC     |   | 0576521     |   |   |
|                                            |   | NL     |   | 0576521     |   |   |
|                                            |   | NO     |   | 307448      |   |   |
|                                            |   | SE     |   | 0576521     |   |   |

 

11

----

 
|   |   | US |   | 5529766 |   |      |
|--------|--------|----|--------|---------|--------|-----------|
|   |   | US |   |    |   | 11/055543 |

 

12

----

 
| METHOD FOR INFUSION OF  ULTRASOUND                                                       |   | AU     |   | 770389      |   |       |
|------------------------------------------------------------------------------------------|--------|--------|--------|-------------|--------|------------|
| CONTRAST AGENTS                                                                          |   | DE     |   | 60006683.5  |   |       |
|                                                                                     |   | EP     |   | 1206286     |   |       |
|                                                                                     |   | ES     |   | 1206286     |   |       |
|                                                                                     |   | FR     |   | 1206286     |   |       |
|                                                                                     |   | GB     |   | 1206286     |   |       |
|                                                                                     |   | IT     |   | 1206286     |   |       |
|                                                                                     |   |   |   |        |   |       |
| CONTRATED STABILIZED  MICROBUBBLE-TYPE ULTRASONIC IMAGING AGENT AND METHOD OF PRODUCTION |   | US     |   |        |   | 139577     |
|                                                                                     |   | DK     |   | 173528      |   |       |
|                                                                                     |   | US     |   | 4844882     |   |       |
|                                                                                     |   | AU     |   | 603718      |   |       |
|                                                                                     |   | AT     |   | 0324938     |   |       |
|                                                                                     |   | BE     |   | 0324938     |   |       |
|                                                                                     |   | DE     |   | P3885730.8  |   |       |
|                                                                                     |   | CH     |   | 0324938     |   |       |
|                                                                                     |   | FR     |   | 0324938     |   |       |
|                                                                                     |   | GB     |   | 0324938     |   |       |
|                                                                                     |   | IT     |   | 0324938     |   |       |
|                                                                                     |   |   |   |        |   |       |
| METHODS FOR SELECTING  AND USING GASES AS ULTRASOUND CONTRAST MEDIA                      |   | AT     |   | E191346     |   |       |
|                                                                                     |   | AU     |   |        |   | 2006200108 |
|                                                                                     |   | BE     |   | 0605477     |   |       |
|                                                                                     |   | BR     |   | PI1100168.2 |   |       |
|                                                                                     |   | BR     |   | PI1100167.4 |   |       |
|                                                                                     |   | CA     |   | 2119129     |   |       |
|                                                                                     |   | CA     |   | 2273140     |   |       |
|                                                                                     |   | CH     |   | 0605477     |   |       |
|                                                                                     |   | CL     |   | 40380       |   |       |
|                                                                                     |   | CZ     |   | 286149      |   |       |
|                                                                                     |   | DE     |   | 69230885    |   |       |
|                                                                                     |   | DK     |   | 0605477     |   |       |
|                                                                                     |   | ES     |   | 0605477     |   |       |
|                                                                                     |   | FI     |   |        |   | 941242     |
|                                                                                     |   | FR     |   | 0605477     |   |       |
|                                                                                     |   | GB     |   | 0605477     |   |       |
|                                                                                     |   | GR     |   | 3033908     |   |       |

 

13

----

 
|                                                               |   | HK     |   | HK1012564  |   |   |
|--------------------------------------------------------------------|--------|--------|--------|------------|--------|--------|
|                                                               |   | HU     |   | 218018     |   |   |
|                                                               |   | ID     |   | ID0014883  |   |   |
|                                                               |   | IE     |   | 0605477    |   |   |
|                                                               |   | IL     |   | 103120     |   |   |
|                                                               |   | IT     |   | 0605477    |   |   |
|                                                               |   | LU     |   | 0605477    |   |   |
|                                                               |   | MC     |   | 0605477    |   |   |
|                                                               |   | MX     |   | 182912     |   |   |
|                                                               |   | MY     |   | MY/111060  |   |   |
|                                                               |   | NL     |   | 0605477    |   |   |
|                                                               |   | NO     |   | 313577     |   |   |
|                                                               |   | NZ     |   | 244341     |   |   |
|                                                               |   | PL     |   | 173817     |   |   |
|                                                               |   | PT     |   | 100867     |   |   |
|                                                               |   | RU     |   | 2114637    |   |   |
|                                                               |   | SE     |   | 0605477    |   |   |
|                                                               |   | SG     |   | 54121      |   |   |
|                                                               |   | TW     |   | 63126      |   |   |
|                                                               |   | US     |   | 5573751    |   |   |
|                                                               |   | US     |   | 5393524    |   |   |
|                                                               |   | US     |   | 5409688    |   |   |
|                                                               |   | US     |   | 5558094    |   |   |
|                                                               |   | US     |   | 6723303    |   |   |
|                                                               |   | US     |   | 5558854    |   |   |
|                                                               |   | US     |   | 6156292    |   |   |
|                                                               |   | US     |   | 6875420    |   |   |
|                                                               |   | US     |   | 6620404    |   |   |
|                                                               |   | ZA     |   | 92/7114    |   |   |
|                                                               |   |   |   |       |   |   |
| ULTRASOUND IMAGING OF  TISSUE PERFUSION BY PULSE ENERGY DISRUPTION |   | US     |   | 6315730    |   |   |
|                                                               |   |   |   |       |   |   |
| IMPROVEMENTS IN OR  RELATING TO CONTRAST AGENTS                    |   | US     |   | 6595925    |   |   |
|                                                               |   |   |   |       |   |   |
| ULTRASONOGRAPHY OF THE  PROSTATE                                   |   | DE     |   | 69831353.4 |   |   |
|                                                               |   | EP     |   | 1039833    |   |   |
|                                                               |   | ES     |   | 1039833    |   |   |
|                                                               |   | FR     |   | 1039833    |   |   |
|                                                               |   | GB     |   | 1039833    |   |   |
|                                                               |   | IT     |   | 1039833    |   |   |
|                                                               |   | US     |   | 6428479    |   |   |
|                                                               |   | US     |   | 6689065    |   |   |

 

14

----

 
| IMPROVEMENTS IN OR  RELATING TO ULTRASONOGRAPHY          |   | US     |   | 6409671 |   |    |
|----------------------------------------------------------|--------|--------|--------|---------|--------|---------|
|                                                     |   |   |   |    |   |    |
| PHASE SHIFT COLLOIDS AS  ULTRASOUND CONTRAST AGENTS      |   | AU     |   | 680652  |   |    |
|                                                     |   | AU     |   | 710508  |   |    |
|                                                     |   | CA     |   | 2154590 |   |    |
|                                                     |   | DE     |   | 0680341 |   |    |
|                                                     |   | EP     |   | 0680341 |   |    |
|                                                     |   | ES     |   | 0680341 |   |    |
|                                                     |   | FR     |   | 0680341 |   |    |
|                                                     |   | GB     |   | 0680341 |   |    |
|                                                     |   | IT     |   | 0680341 |   |    |
|                                                     |   | PL     |   | 176870  |   |    |
|                                                     |   | US     |   | 5595723 |   |    |
|                                                     |   | US     |   | 5707607 |   |    |
|                                                     |   | US     |   | 5876696 |   |    |
|                                                     |   | US     |   | 5558853 |   |    |
|                                                     |   | US     |   | 6569404 |   |    |
|                                                     |   | US     |   | 6245319 |   |    |
|                                                     |   | US     |   | 5558855 |   |    |
|                                                     |   | US     |   | 5707606 |   |    |
|                                                     |   |   |   |    |   |    |
| GAS-FILLED MICROSPHERES  WITH FLUORINE-CONTAINING SHELLS |   | AU     |   | 703652  |   |    |
|                                                     |   | CA     |   |    |   | 2196599 |
|                                                     |   | DE     |   | 0769969 |   |    |
|                                                     |   | EP     |   | 0769969 |   |    |
|                                                     |   | ES     |   | 0769969 |   |    |
|                                                     |   | FR     |   | 0769969 |   |    |
|                                                     |   | GB     |   | 0769969 |   |    |
|                                                     |   | IT     |   | 0769969 |   |    |
|                                                     |   | US     |   | 5562893 |   |    |

 

15

----

 
| USE OF PRESSURE  RESISTANT PROTEIN MICROSPHERES ENCAPSULATING GASES AS ULTRASONIC IMAGING  AGENTS FOR VASCULAR PERFUSION |   | CA     |   |        |   | 2253734    |
|--------------------------------------------------------------------------------------------------------------------------|--------|--------|--------|-------------|--------|------------|
|                                                                                                                     |   | DE     |   | 69732568.7  |   |       |
|                                                                                                                     |   | EP     |   | 0907380     |   |       |
|                                                                                                                     |   | ES     |   | 0907380     |   |       |
|                                                                                                                     |   | FR     |   | 0907380     |   |       |
|                                                                                                                     |   | GB     |   | 0907380     |   |       |
|                                                                                                                     |   | IT     |   | 0907380     |   |       |
|                                                                                                                     |   | US     |   | 5976501     |   |       |
|                                                                                                                     |   |   |   |        |   |       |
| SENTINEL LYMPH NODE  DETECTION                                                                                           |   | AU     |   |        |   | 2003272154 |
|                                                                                                                     |   | US     |   |        |   | 10/530094  |
|                                                                                                                     |   |   |   |        |   |       |
| CONTRAST AGENTS FOR  ULTRASONIC IMAGING                                                                                  |   | AT     |   | 0224934     |   |       |
|                                                                                                                     |   | AU     |   | 575735      |   |       |
|                                                                                                                     |   | BE     |   | 0224934     |   |       |
|                                                                                                                     |   | CA     |   | 1274773     |   |       |
|                                                                                                                     |   | CH     |   | 0224934     |   |       |
|                                                                                                                     |   | DE     |   | 0224934     |   |       |
|                                                                                                                     |   | EP     |   | 0224934     |   |       |
|                                                                                                                     |   | FR     |   | 0224934     |   |       |
|                                                                                                                     |   | GB     |   | 0224934     |   |       |
|                                                                                                                     |   | IT     |   | 0224934     |   |       |
|                                                                                                                     |   | NL     |   | 0224934     |   |       |
|                                                                                                                     |   | SE     |   | 0224934     |   |       |
|                                                                                                                     |   |   |   |        |   |       |
| CONTRAST AGENTS  CONSISTING OF GALACTOSE PARTICLES AND AN AMPHIPHILIC CARBOXYLIC ACID                                    |   | DE     |   | P69319888.5 |   |       |
|                                                                                                                     |   | EP     |   | 0620743     |   |       |
|                                                                                                                     |   | US     |   | 5567412     |   |       |
|                                                                                                                     |   | US     |   | 5614169     |   |       |
|                                                                                                                     |   |   |   |        |   |       |
| IMPROVEMENTS IN OR RELATING  TO CONTRAST AGENTS                                                                          |   | CA     |   | 2127705     |   |       |

 

16

----

 
|                                                                |   | EP     |   |        |   | 99203253.2 |
|---------------------------------------------------------------------|--------|--------|--------|-------------|--------|------------|
|                                                                |   | US     |   | 5558856     |   |       |
|                                                                |   | US     |   | 5827502     |   |       |
|                                                                |   | US     |   |        |   | 11/055544  |
|                                                                |   |   |   |        |   |       |
| IMPROVEMENTS IN  CONTRAST AGENTS, CONSISTING OF GALACTOSE PARTICLES |   | US     |   | 5637289     |   |       |
|                                                                |   | US     |   | 5648062     |   |       |
|                                                                |   | US     |   | 5928626     |   |       |
|                                                                |   |   |   |        |   |       |
| IMPROVEMENTS IN OR  RELATING TO CONTRAST AGENTS                     |   | DE     |   | P69326447.0 |   |       |
|                                                                |   | EP     |   | 0627942     |   |       |
|                                                                |   | GB     |   | 0627942     |   |       |
|                                                                |   | IT     |   | 0627942     |   |       |
|                                                                |   | US     |   | 5795562     |   |       |
|                                                                |   | US     |   | 5674468     |   |       |
|                                                                |   | US     |   | 5676925     |   |       |
|                                                                |   |   |   |        |   |       |
| IMPROVEMENTS IN OR  RELATING TO CONTRAST AGENTS                     |   | US     |   | 5718884     |   |       |
|                                                                |   |   |   |        |   |       |
| IMPROVEMENTS IN OR  RELATING TO CONTRAST AGENTS                     |   | DE     |   | P69425136.4 |   |       |
|                                                                |   | EP     |   | 0689461     |   |       |

 

17

----

 
| MEDICAL USE OF ORGANIC  AEROGELS AND BIODEGRADABLE ORGANIC AEROGELS                 |   | DE     |   | 69425573.4 |   |      |
|-------------------------------------------------------------------------------------|--------|--------|--------|------------|--------|-----------|
|                                                                                |   | EP     |   | 0707474    |   |      |
|                                                                                |   | GB     |   | 0707474    |   |      |
|                                                                                |   |   |   |       |   |      |
| POLYMERIC  SURFACTANT-ENCAPSULATED MICROBUBBLES AND THEIR USE IN ULTRASOUND IMAGING |   | DE     |   | 69430432.8 |   |      |
|                                                                                |   | EP     |   | 0717658    |   |      |
|                                                                                |   | ES     |   | 0717658    |   |      |
|                                                                                |   | FR     |   | 0717658    |   |      |
|                                                                                |   | GB     |   | 0717658    |   |      |
|                                                                                |   | IT     |   | 0717658    |   |      |
|                                                                                |   | US     |   | 5919434    |   |      |
|                                                                                |   | US     |   | 5990263    |   |      |
|                                                                                |   |   |   |       |   |      |
| IMPROVEMENTS IN OR  RELATING TO CONTRAST AGENTS                                     |   | US     |   | 6274120    |   |      |
|                                                                                |   |   |   |       |   |      |
| IMPROVEMENTS IN OR  RELATING TO CONTRAST AGENTS                                     |   | DE     |   | 69526093.6 |   |      |
|                                                                                |   | EP     |   | 0779821    |   |      |
|                                                                                |   | ES     |   | 0779821    |   |      |
|                                                                                |   | FR     |   | 0779821    |   |      |
|                                                                                |   | GB     |   | 0779821    |   |      |
|                                                                                |   | IT     |   | 0779821    |   |      |
|                                                                                |   |   |   |       |   |      |
| IMPROVEMENTS IN OR  RELATING TO ULTRASOUND IMAGING                                  |   | US     |   | 5980460    |   |      |
|                                                                                |   | US     |   | 5601085    |   |      |
|                                                                                |   |   |   |       |   |      |
| IMPROVEMENTS IN OR  RELATING TO DIAGNOSTIC/THERAPEUTIC AGENTS                       |   | EP     |   | 0973552    |   |      |
|                                                                                |   | GB     |   | 0973552    |   |      |
|                                                                                |   | US     |   | 6264917    |   |      |
|                                                                                |   | US     |   | 6261537    |   |      |
|                                                                                |   | US     |   |       |   | 10/722075 |

 

18

----

 
| IMPROVEMENTS IN OR  RELATING TO DIAGNOSTIC/THERAPEUTIC AGENTS                                |   | US     |   | 6331289 |   |      |
|----------------------------------------------------------------------------------------------|--------|--------|--------|---------|--------|-----------|
|                                                                                         |   | US     |   | 6680047 |   |      |
|                                                                                         |   |   |   |    |   |      |
| CONTRAST AGENTS CONTAINING  TWO TYPES OF GAS FILLED MICROBUBBLES                             |   | US     |   | 6054118 |   |      |
|                                                                                         |   |   |   |    |   |      |
| IMPROVEMENTS IN OR  RELATING TO DIAGNOSTIC/THERAPEUTIC AGENTS                                |   | US     |   | 6548048 |   |      |
|                                                                                         |   |   |   |    |   |      |
| IMPROVEMENTS IN OR  RELATING TO CONTRAST AGENTS                                              |   | AU     |   | 745047  |   |      |
|                                                                                         |   | DE     |   | 1007100 |   |      |
|                                                                                         |   | EP     |   | 1007100 |   |      |
|                                                                                         |   | ES     |   | 1007100 |   |      |
|                                                                                         |   | FR     |   | 1007100 |   |      |
|                                                                                         |   | GB     |   | 1007100 |   |      |
|                                                                                         |   | HU     |   | 224218  |   |      |
|                                                                                         |   | IT     |   | 1007100 |   |      |
|                                                                                         |   | MX     |   |    |   | 9903664   |
|                                                                                         |   | US     |   | 6375931 |   |      |
|                                                                                         |   | US     |   | 6783752 |   |      |
|                                                                                         |   |   |   |    |   |      |
| CONTRAST AGENTS  COMPRISING AN AZEOTROPIC MIXTURE OF TWO GASES FOR ULTRASOUND INVESTIGATIONS |   | US     |   | 6177061 |   |      |
|                                                                                         |   |   |   |    |   |      |
| ULTRASOUND IMAGING WITH  CONTRAST AGENT TARGETED TO MICROVASCULATURE AND A VASODILATOR DRUG  |   | US     |   | 6811766 |   |      |
|                                                                                         |   | US     |   |    |   | 10/867237 |

 

19

----

 
| APPARATUS HAVING  PARTIALLY GOLD-PLATED SURFACE                               |   | US     |   |       |   | 10/761967 |
|-------------------------------------------------------------------------------|--------|--------|--------|------------|--------|-----------|
|                                                                          |   |   |   |       |   |      |
| ULTRASOUND CONTRAST  AGENT DISPERSIONS COMPRISING GAS AND DESTABILISING AGENT |   | DE     |   | 69921317.7 |   |      |
|                                                                          |   | EP     |   | 1079865    |   |      |
|                                                                          |   |   |   |       |   |      |
| CONTRAST AGENTS                                                               |   | US     |   |       |   | 10/717196 |

 

 

20

----